Phenotypes Associated with This Genotype

Genotype
MGI:5581952

• Allelic Composition: Ctnnb1^tm2Kem/Ctnnb1⁺; Pparg^{tm1.1(tTA)Jmgr}/Pparg⁺; Tg(tetO-cre)1Jaw/0
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

skeleton

skeleton phenotype ( J:178340 )

N • doxycycline-treated mice exhibit normal numbers of osteoblasts, bone formation and bone mineral apposition rates

increased osteoclast cell number ( J:178340 )

• in doxycycline-treated mice

abnormal osteoclast physiology ( J:178340 )

• doxycycline-treated bone marrow cultures exhibit reduced osteoclast precursor proliferation compared with control cultures

abnormal trabecular bone morphology ( J:178340 )

• decreased bone surface in doxycycline-treated mice

decreased trabecular bone volume ( J:178340 )

• trabecular, cortical and total in doxycycline-treated mice

decreased bone trabecula number ( J:178340 )

• with increased spacing in doxycycline-treated mice

decreased trabecular bone mass ( J:178340 )

• in doxycycline-treated mice

decreased trabecular bone thickness ( J:178340 )

• in doxycycline-treated mice

osteoporosis ( J:178340 )

• in doxycycline-treated mice

increased bone resorption ( J:178340 )

• in doxycycline-treated mice

hematopoietic system

increased osteoclast cell number ( J:178340 )

• in doxycycline-treated mice

abnormal osteoclast physiology ( J:178340 )

• doxycycline-treated bone marrow cultures exhibit reduced osteoclast precursor proliferation compared with control cultures

immune system

increased osteoclast cell number ( J:178340 )

• in doxycycline-treated mice

abnormal osteoclast physiology ( J:178340 )

• doxycycline-treated bone marrow cultures exhibit reduced osteoclast precursor proliferation compared with control cultures